DUBLIN--(BUSINESS WIRE)--The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA.
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.
Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.
Market Trends
- High cost of RA drugs
- Use of biologics/biosimilars for treatment of RA
- Use of gene therapy for RA treatment
- Market dominance by TNF-alpha inhibitors
- Need for rheumatologists
Key Players
- AbbVie
- Amgen
- Johnson & Johnson
- Novartis
- Pfizer
- UCB Pharma
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
- Pipeline analysis
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE
- Segmentation by type of molecule
- Comparison by type of molecule
- Biologics - Market size and forecast 2017-2022
- Small molecules - Market size and forecast 2017-2022
- Market opportunity by type of molecule
PART 09: MARKET SEGMENTATION BY TYPE OF RA
- Segmentation by type of RA
- Seropositive RA
- Seronegative RA
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: MARKET TRENDS
- High cost of RA drugs
- Use of biologics/biosimilars for treatment of RA
- Use of gene therapy for RA treatment
- Market dominance by TNF-alpha inhibitors
- Need for rheumatologists
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Amgen
- Johnson & Johnson
- Novartis
- Pfizer
- UCB Pharma
For more information about this report visit https://www.researchandmarkets.com/research/bk8l6p/global_rheumatoid?w=4
